Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.93 USD | +0.18% | +1.99% | +62.16% |
Financials (USD)
Sales 2024 * | 15.95B | Sales 2025 * | 16.54B | Capitalization | 19.17B |
---|---|---|---|---|---|
Net income 2024 * | 820M | Net income 2025 * | 1.39B | EV / Sales 2024 * | 2.14 x |
Net Debt 2024 * | 14.93B | Net Debt 2025 * | 12.41B | EV / Sales 2025 * | 1.91 x |
P/E ratio 2024 * |
17.9
x | P/E ratio 2025 * |
12.3
x | Employees | 35,737 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.44% |
Latest transcript on Teva Pharmaceutical Industries Limited
1 day | +0.18% | ||
1 week | +1.99% | ||
1 month | +20.50% | ||
3 months | +28.75% | ||
6 months | +72.40% | ||
Current year | +62.16% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 22-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 19-12-21 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 15-08-31 |
Janet Vergis
BRD | Director/Board Member | 59 | 20-06-08 |
Sol Barer
CHM | Chairman | 76 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.38% | 13 M€ | -.--% | ||
0.27% | 17 M€ | +6.09% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 16.93 | +0.18% | 12,778,976 |
24-05-30 | 16.9 | +2.74% | 6,426,290 |
24-05-29 | 16.45 | -1.85% | 5,132,797 |
24-05-28 | 16.76 | +0.96% | 6,833,385 |
24-05-24 | 16.6 | -0.95% | 6,584,096 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.16% | 19.17B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- TEVA Stock